A massive write up for PIR in the September issue.The upshot - Best discovery globally for some years, 10Moz+ potential, share price target on current market metrics of $3.67....Time will tellMG
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%